Chotcomwongse Peranut, Ruamviboonsuk Paisan, Karavapitayakul Chaiwat, Thongthong Koblarp, Amornpetchsathaporn Anyarak, Chainakul Methaphon, Triprachanath Malee, Lerdpanyawattananukul Eckachai, Arjkongharn Niracha, Ruamviboonsuk Varis, Vongsa Nattaporn, Pakaymaskul Pawin, Waiwaree Turean, Ruampunpong Hathaiphan, Tiwari Richa, Tangcharoensathien Viroj
Department of Ophthalmology, College of Medicine, Rajavithi Hospital, Rangsit University, Bangkok, Thailand.
Department of Medical Services (DMS), Ministry of Public Health, Nonthaburi, Thailand.
Ophthalmol Ther. 2025 Feb;14(2):447-460. doi: 10.1007/s40123-024-01086-8. Epub 2025 Jan 10.
Screening diabetic retinopathy (DR) for timely management can reduce global blindness. Many existing DR screening programs worldwide are non-digital, standalone, and deployed with grading retinal photographs by trained personnel. To integrate the screening programs, with or without artificial intelligence (AI), into hospital information systems to improve their effectiveness, the non-digital workflow must be transformed into digital. We developed a cloud-based digital platform and implemented it in an existing DR screening program.
We conducted the following processes in the platform for prospective DR screening at a community hospital: capturing patients' retinal photographs, uploading them for grading by AI or trained personnel on alternate weeks for 32 weeks, and referring vision-threatening DR to a referral center. At this center, the platform was applied for the assessment of potential missed referrals via remote over-reading by a retinal specialist and tracking referrals. Implementational outcomes, such as detecting positive cases, agreement between AI and over-reading, and referral adherence were assessed.
Of 645 patients screened by AI, 201 (31.2%) were referrals, 129 (64.2%) of which were true positives agreeable by over-reading; 115 of these true positives (89.1%) had referral adherence. False negatives judged by over-reading were 1.1% (5/444). Of 730 patients in manual screening, 175 (24.0%) were potential referrals, 11 (6.3%) of which were referred at the point-of-screening; eight of these (72.7%) adhered to referral. The remaining 164 cases were appointed for later examination by a visiting general ophthalmologist; 11 of these 116 examined (9.5%) were referred for non-DR-related eye conditions with 81.8% (9/11) referral adherence. No system failure or interruption was found.
The digital platform can be practically integrated into the existing non-digital DR screening programs to implement AI and monitor previously unknown but important indicators, such as referral adherence, to improve the effectiveness of the programs.
ClinicalTrials.gov. (registration number: NCT05166122).
筛查糖尿病视网膜病变(DR)以便及时进行治疗可减少全球范围内的失明现象。全球许多现有的DR筛查项目都是非数字化的、独立运行的,由经过培训的人员对视网膜照片进行分级。为了将有无人工智能(AI)参与的筛查项目整合到医院信息系统中以提高其有效性,必须将非数字化工作流程转变为数字化流程。我们开发了一个基于云的数字平台,并在现有的DR筛查项目中实施。
我们在社区医院的该平台上进行了以下前瞻性DR筛查流程:拍摄患者的视网膜照片,每隔一周上传照片由AI或经过培训的人员进行分级,持续32周,然后将有视力威胁的DR患者转诊至转诊中心。在该中心,通过视网膜专科医生远程复核来应用该平台评估潜在的漏诊转诊情况并跟踪转诊情况。评估了实施结果,如检测出阳性病例、AI与复核结果之间的一致性以及转诊依从性。
在由AI筛查的645例患者中,201例(31.2%)被转诊,其中129例(64.2%)经复核为真正的阳性病例;这些真正的阳性病例中有115例(89.1%)转诊依从。经复核判断的假阴性为1.1%(5/444)。在人工筛查的730例患者中,175例(24.0%)为潜在转诊患者,其中11例(6.3%)在筛查时被转诊;其中8例(72.7%)转诊依从。其余164例安排由来访的普通眼科医生进行后续检查;在这116例接受检查的患者中,11例(9.5%)因非DR相关眼部疾病被转诊,转诊依从率为81.8%(9/11)。未发现系统故障或中断情况。
该数字平台可切实整合到现有的非数字化DR筛查项目中,以实施AI并监测转诊依从性等以前未知但很重要的指标,从而提高项目的有效性。
ClinicalTrials.gov。(注册号:NCT05166122)